FDA OKs Neuron Therapeutics' lumbar catheter:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared for sale Neuron Therapeutics' lumbar catheter for draining cerebrospinal fluid (CSF) from the space surrounding the spinal cord. Compared with existing lumbar drainage products, the new catheter can transport CSF at significantly higher flow rates, is less likely to collapse or become obstructed and has improved handling characteristics, claims the Malvern, Pennsylvania firm. The catheter is part of Neuron's investigational drug delivery system for treating central nervous system disorders, such as subarachnoid haemorrhage, spinal cord injury, traumatic brain injury and stroke.
You may also be interested in...
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.